Optimizing NMOSD Care: Navigating Relapse Risks and Treatment Choices
Experts examine the evolving NMOSD treatment landscape, focusing on rituximab's safety concerns, comparative effectiveness of FDA-approved therapies, hospitalization rates, and strategies for optimizing patient outcomes through informed treatment selection and management approaches.
EP. 1: Current Treatment Landscape of AQP4-IgG+ NMOSD and Considerations on Relapse Rates
November 18th 2024Video
Michael Levy, MD, PhD, discusses how Aquaporin-4 IgG-seropositive neuromyelitis optica spectrum disorder (AQP4-IgG+ NMOSD) is a rare autoimmune condition affecting the central nervous system. Anti-CD20 therapies, particularly rituximab, have led to increased relapse rates.
